Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Increased to Strong-Buy at Baird R W

Baird R W upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $28.00 target price for the company. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. HC Wainwright raised their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $32.25.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $23.09 on Monday. The business has a 50 day simple moving average of $22.03 and a two-hundred day simple moving average of $20.83. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 2.25 and a beta of 0.80. Catalyst Pharmaceuticals has a one year low of $13.12 and a one year high of $24.64.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock valued at $1,754,140 over the last ninety days. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after acquiring an additional 33,888 shares in the last quarter. Wellington Management Group LLP purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $1,185,000. Redhawk Wealth Advisors Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter worth about $1,273,000. GSA Capital Partners LLP purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $625,000. Finally, Capstone Investment Advisors LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $708,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.